Is YDES or ZVRA more undervalued in 2026?

CirclFi compares YD Bio Limited (YDES) and Zevra Therapeutics, Inc. (ZVRA) using 13 institutional-grade valuation models. YDES has a Quality of Company score of 2.3/10 while ZVRA scores 6.8/10.

Which is a better buy — YDES or ZVRA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do YDES and ZVRA valuations compare?

YDES at $3.51 and ZVRA at $11.40 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

YDES vs ZVRA Valuation Comparison 2026 — Intrinsic Value Analysis

YDES

Biotechnology

YD Bio Limited

Quality

2.3

out of 10

Value Trap

—

Price

$3.51

Last close

Models

10/13

Active

ZVRA

Biotechnology

Zevra Therapeutics, Inc.

Quality

6.8

out of 10

Value Trap

LOW

Price

$11.40

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	YDES Fair Value	YDES Upside	ZVRA Fair Value	ZVRA Upside
Bayesian DCF	Intrinsic	$0.93	-73.5%	$7.88	-30.9%
Earnings Power Value	Intrinsic	$0.12	-97.5%	$8.07	-29.2%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for YDES vs ZVRA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

YDES vs ZVRA — Which Stock Is More Undervalued?

ZVRA scores higher with a 6.8/10 quality rating vs YDES's 2.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing YD Bio Limited (YDES) and Zevra Therapeutics, Inc. (ZVRA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

YDES currently trades at $3.51 with a QOC of 2.3/10, while ZVRA trades at $11.40 with a QOC of 6.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).